Common side effects
Based on the Phase 2 trial (48 weeks, 338 participants), the most commonly reported side effects were gastrointestinal. Most were mild to moderate in severity and improved over time as the body adjusted to the medication.
| Side Effect | Frequency (Phase 2) | Severity | Notes |
|---|---|---|---|
| Nausea | Very common | Mild-moderate | Most common early, decreased over time |
| Diarrhea | Common | Mild-moderate | Generally manageable |
| Vomiting | Common | Mild-moderate | Dose-dependent |
| Decreased appetite | Common | Mild | Expected mechanism of action |
| Constipation | Common | Mild | Similar to other incretin drugs |
| Injection site reaction | Occasional | Mild | Redness, itching at injection site |
| Heart rate increase | Common | Mild (2-6 bpm) | Class effect of incretin agonists |
Managing gastrointestinal side effects
In clinical trials, GI side effects were managed with standard approaches:
- Dose titration: Starting at a low dose and gradually increasing over weeks to months significantly reduces GI side effects
- Dietary adjustments: Eating smaller meals, avoiding high-fat foods, and staying hydrated
- Timing: Some participants found injecting before bed reduced daytime nausea
- Persistence: Most GI side effects improve or resolve within the first few weeks to months of treatment
Serious risks and theoretical concerns
Thyroid C-cell tumors
GLP-1 receptor agonists have caused thyroid C-cell tumors in rodent studies. It is unknown whether this applies to humans. Retatrutide is:
- Contraindicated in people with personal or family history of medullary thyroid carcinoma (MTC)
- Contraindicated in people with Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- Under monitoring in ongoing Phase 3 trials for any signal of thyroid malignancy
Pancreatitis
Acute pancreatitis has been observed with other GLP-1 receptor agonists, though it is rare. The Phase 2 retatrutide trial did not report pancreatitis cases, but the sample size was too small to detect rare events. Phase 3 trials with thousands of participants will provide better data.
Gallbladder disease
Rapid weight loss increases the risk of gallstones and gallbladder inflammation (cholecystitis). This risk applies to all significant weight loss, regardless of method. GLP-1 agonists have been associated with increased rates of gallbladder events.
Hypoglycemia
Retatrutide stimulates insulin secretion in a glucose-dependent manner, meaning it generally does not cause low blood sugar on its own. However, when combined with insulin or sulfonylureas (in people with diabetes), the risk of hypoglycemia increases.
Cardiovascular effects
Mild heart rate increases (2-6 beats per minute) were observed, consistent with other incretin-based therapies. The long-term cardiovascular impact is being studied in TRIUMPH-3, the dedicated cardiovascular outcomes trial.
What we don't know yet
Retatrutide is still in Phase 3 trials. Important safety questions that ongoing research aims to answer:
- Long-term safety: What happens after 2, 5, or 10 years of use? The longest data is 48 weeks from Phase 2.
- Rare adverse events: Phase 2 enrolled 338 people — too few to detect events occurring in 1 in 1,000+ patients.
- Cardiovascular outcomes: Does retatrutide reduce heart attacks and strokes? (TRIUMPH-3 will answer this.)
- Pregnancy safety: Retatrutide has not been studied in pregnancy. Women of childbearing potential were required to use contraception in trials.
- Drug interactions: Limited data on interactions with other medications, including oral contraceptives (which may have reduced absorption due to delayed gastric emptying).
- Glucagon-specific risks: Because retatrutide is the first triple agonist including glucagon activation to reach Phase 3, the long-term effects of chronic glucagon receptor activation in humans are not fully characterized.